BACKGROUND: Cardiovascular disease (CVD) risk is an important health concern among survivors of breast cancer. However, few studies to date have examined whether trajectories of CVD risk and major risk factors are worse among women with a breast cancer diagnosis compared with those without. METHODS: Changes in weight, body mass index, waist circumference, systolic blood pressure, and 10-year CVD risk were compared between women with (813 women) and without (1049 women) an incident breast cancer diagnosis while they were enrolled in the National Institute of Environmental Health Sciences Sister Study cohort. Blood pressure and adiposity measures were collected by trained examiners at an enrollment visit (≥1 year before breast cancer diagnosis) and a second home visit 4 to 11 years later (≥1 year after breast cancer diagnosis). The non-laboratory-based Framingham risk score, a measure of 10-year general CVD risk, was calculated at both the enrollment and second visits. All analyses were stratified by menopausal status at the time of enrollment. RESULTS: Women who were premenopausal at the time of enrollment experienced moderate increases in weight, waist circumference, systolic blood pressure, and CVD risk over the study period. Those who were postmenopausal at the time of enrollment demonstrated little change in weight, but were found to have increases in waist circumference, systolic blood pressure, and CVD risk. In both groups, changes over time did not differ significantly according to breast cancer status. Neither chemotherapy nor endocrine therapy were found to be associated with greater increases in CVD risk or risk factors. CONCLUSIONS: In the current study cohort, changes over time in CVD risk, adiposity measures, and blood pressure were similar between women who developed an incident breast cancer and those who did not. Cancer 2018;124:4512-4519. © 2018 American Cancer Society.
INTRODUCTION
Breast cancer mortality rates have fallen by an average of 1.8% per year over the past decade, due largely to improvements in treatment and screening. 1 Currently, there are >3.5 million survivors of breast cancer living in the United States, and this number is projected to surpass 4.5 million by the year 2026. 2 Thus, any unique long-term health concerns of this growing population are increasingly becoming a research priority.
Cardiovascular disease (CVD) is a key contributor to mortality among women with breast cancer, and is the leading cause of death for women with ductal carcinoma in situ or stage I disease, and for women aged ≥80 years with stage II disease. [3] [4] [5] Recent evidence also supports a higher risk of CVD mortality among women with a breast cancer history compared with their cancer-free peers. 6 Cardiotoxic cancer treatments, including anthracycline-based chemotherapy and trastuzumab, have been identified as contributors to CVD risk among survivors of breast cancer. 7 However, a higher burden of traditional CVD risk factors such as obesity and hypertension also could play an important role. Understanding trajectories of CVD risk and major risk factors among women diagnosed with breast cancer may aide in the design of appropriately timed and targeted interventions to prevent CVD events in this population. However, to the best of our knowledge, few studies to date have examined longitudinal patterns of CVD risk among women with breast cancer, or have compared changes over time with those of a breast cancer-free comparison group.
In the current study, we evaluated changes in CVD risk factors and estimated 10-year CVD risk from before to after diagnosis among women with an incident breast cancer in the National Institute of Environmental Health Sciences
Cancer December 1, 2018 (NIEHS) Sister Study cohort, and compared these changes with those of women from the same cohort who remained free of breast cancer over the same time period.
MATERIALS AND METHODS

Study Population
The NIEHS Sister Study is a prospective cohort designed to identify genetic and environmental risk factors for breast cancer. 8 Between 2003 and 2009, women from the United States and Puerto Rico were recruited into the Sister Study through a national multimedia campaign and a network of breast cancer professionals and volunteers. Eligible women were aged 35 years to 74 years and free of breast cancer themselves at the time of enrollment, but had a sister who had been diagnosed with breast cancer. Participants completed questionnaires at enrollment for the assessment of medical conditions, medication use, and sociodemographic and lifestyle information. For women who developed an incident breast cancer (invasive or ductal carcinoma in situ), medical records were abstracted to collect information regarding disease stage and treatments received, including chemotherapy and endocrine therapy. If these data were missing from the medical records, or if the medical records were unavailable, information was taken from self-reported measures on a questionnaire completed by Sister Study participants approximately 6 months after their incident breast cancer diagnosis. The study was approved by the institutional review board of the NIEHS, the National Institutes of Health, and the Copernicus Group. All participants provided written informed consent.
At the time of enrollment, all Sister Study participants completed a home visit for the collection of biological samples and blood pressure and anthropometric measures. In 2014, a second home visit was conducted among a subset of Sister Study participants (Fig. 1 ). All women who had developed an incident breast cancer since the time of enrollment were invited to participate (1909 women), as was a randomly selected 4% subcohort (1828 women). Of those invited, 1215 women and 1207 women, respectively, with and without a diagnosis of breast cancer completed the second home visit (participation rates of 64% and 66%, respectively). For these analyses, we further excluded women with a diagnosis of lobular carcinoma in situ (31 women); women with a self-reported history of heart attack, angina, heart failure, stroke, or transient ischemic attack at the time of enrollment (105 women); and those women for whom information regarding CVD risk and risk factors was missing (9 women). Because the estimated CVD risk measure used in these analyses originally was developed among Framingham Heart Study participants aged 30 years to 74 years, 9 we also excluded all women aged >74 years at the time of the second home visit (270 women). Among women with breast cancer, we further excluded those with <1 year between either enrollment and the time of breast cancer diagnosis (134 women) or breast cancer diagnosis and the second home visit (7 women), and those with AJCC stage IV disease (4 women).
CVD Risk Factor Assessment
All anthropometric and blood pressure measures were collected by trained study personnel using the same standardized protocols at both the enrollment and second home visits. Height and weight were measured without shoes, and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m 2 ). Waist circumference was measured over skin or lightweight clothing at the midpoint between the lowest rib on the right side and the top of the iliac crest. For blood pressure measurement, 3 readings obtained approximately 1 to 2 minutes apart were taken in a seated position. Measurements were taken from alternating arms, starting with the left arm (Left RightLeft). If both arms could not be used, 3 readings were taken from the available arm. The average of the 3 readings was used in all analyses. For women who reported taking antihypertensive medication on questionnaires completed at either enrollment or the second home visit, we added a constant of 15 mm Hg to their measured systolic blood pressure from that visit (474 women noting antihypertensive medication use at enrollment and 658 women noting it at the second visit) to adjust for treatment effects. 10 Smoking status and prevalent diabetes were ascertained via questionnaires completed at the enrollment and second home visits.
For each home visit, we calculated the non-laboratory-based version of the Framingham risk measure, a multivariable risk factor algorithm used to assess the 10-year risk of general CVD, defined in the Framingham Heart Study as a composite of coronary heart disease, cerebrovascular events, peripheral artery disease, and heart failure. 9 This risk measure incorporates information regarding age, diabetes, smoking, treated and untreated systolic blood pressure, and BMI, and has good discrimination compared with the full, laboratory-based Framingham risk model. 9 
Statistical Analysis
Outcomes included changes in weight, BMI, waist circumference, systolic blood pressure, and 10-year CVD risk, calculated as the difference between the second home visit and enrollment measures. General linear models, with change as the outcome, were used to compare CVD risk and risk factor trajectories between women with and without breast cancer. All models were adjusted for the enrollment measure, age at enrollment, and time between the enrollment and second home visits. Due to evidence of differing trajectories between premenopausal and postmenopausal women, all analyses were stratified by menopausal status at the time of enrollment onto the Sister Study. We then conducted further analyses stratified by BMI at the time of enrollment and, among women who were premenopausal at enrollment, by menopausal status at the second home visit. To evaluate associations between chemotherapy and/or endocrine therapy and changes in CVD risk and risk factors, we performed subgroup analyses restricting the breast cancer group to only those women who had received these therapies. Among women who were premenopausal at the time of enrollment, we also examined changes in CVD risk and risk factors according to menopausal status at the time of diagnosis (ie, premenopausal or postmenopausal breast cancer). In sensitivity analyses, we excluded women who reported a diagnosis of angina, heart failure, heart attack, transient ischemic attack, or stroke between the time of enrollment and the second home visit (71 women). We also performed sensitivity analyses using measured systolic blood pressure values that were not corrected for antihypertensive medication use.
RESULTS
The average ages at the time of enrollment among participants with and without an incident breast cancer diagnosis were 47 years and 46 years, respectively, among women who were premenopausal at the time of enrollment and 59 years and 58 years, respectively, among women who were postmenopausal at the time of enrollment (Table 1) . Overall, the median time between the enrollment and second home visits was 7.8 years (interquartile range, 6.5 years-8.7 years; range, 4.4 years-10.8 years). Regardless of menopausal status at the time of enrollment or incident breast cancer status, the majority of participants were non-Hispanic white, held a Bachelor's degree or higher, and were never-smokers.
Among women who were premenopausal at the time of enrollment, neither CVD risk nor any of the risk factors measured were found to differ substantially at either the enrollment or second home visits between women who did and those who did not develop breast cancer during the study period (see Supporting Table 1 ). Waist circumference measured at the time of enrollment appeared somewhat larger among postmenopausal women who went on to develop breast cancer compared with those who did not (87.4 cm vs 85.7 cm), but no other measures were found to differ substantially between the groups at either time point.
Among women who were premenopausal at the time of enrollment, the 10-year CVD risk increased by an average of 2.7% and 2.8%, respectively, among those who did and those who did not go on to develop breast cancer (P=.867) ( Table 2) . Changes in weight, BMI, waist circumference, and systolic blood pressure also were found to be similar between groups. No substantial differences in CVD risk or risk factor changes were observed between women with and without breast cancer in analyses stratified by either BMI at the time of enrollment or menopausal status at the second home visit, in analyses restricted to women treated with chemotherapy and/or endocrine therapy, or in analyses according to menopausal status at the time of diagnosis. Changes according to incident breast cancer status also generally were similar among women who were postmenopausal at the time of enrollment, although the increase in systolic blood pressure was smaller among women with breast cancer who were treated with chemotherapy without endocrine therapy compared with among women without breast cancer (0.3 mm Hg vs 4.8 mm Hg; P=.036) ( Table 3) . Interpretations were unchanged when women with a diagnosis of angina, heart failure, heart attack, transient ischemic attack, or stroke were excluded, and when uncorrected systolic blood pressure values were used in analyses (data not shown).
DISCUSSION
In the current of study of nearly 2000 women enrolled in the prospective Sister Study cohort, prediagnosis to postdiagnosis changes in CVD risk and risk factors among women with an incident breast cancer diagnosis did not appear to differ substantially from changes among similarly aged women who remained free of breast cancer over the same time period. Regardless of incident breast cancer status, women who were premenopausal at the time of enrollment experienced, on average, modest gains in
CVD risk, weight, waist circumference, and blood pressure over the 4-year to 11-year period. Among women who were postmenopausal at the time of enrollment, weight remained relatively stable, whereas waist circumference, systolic blood pressure, and CVD risk increased to a similar extent among women with and without breast cancer. These patterns held in analyses that were limited to women who received either chemotherapy or endocrine therapy.
With the improvements in breast cancer survival made over the past few decades, the risk of CVD has increasingly become a priority health concern among survivors of breast cancer. A recent systematic review examined the risk of CVD mortality after breast cancer, and concluded that approximately 2% to 10% of women with breast cancer die of CVD, and that CVD mortality is elevated among women with breast cancer compared with women without a breast cancer history. 6 Similar to women in the general population, traditional risk factors for CVD, such as hypertension and excess adiposity, have been associated with CVD incidence and mortality among survivors of breast cancer. [11] [12] [13] However, to our knowledge, whether breast cancer and its treatment exacerbate these risk factors, contributing to greater increases in CVD risk over time compared with among Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease. a Adjusted for age at enrollment, time between enrollment and second visit, and enrollment measure.
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In the current analyses, we used the non-laboratory-based Framingham risk measure (an estimate of 10-year general CVD risk that integrates information regarding age, diabetes, smoking, BMI, and treated and untreated systolic blood pressure) to compare changes in risk according to breast cancer status. Although to our knowledge this risk score has not been validated among women with breast cancer, and may underestimate the absolute risk in this population because it does not incorporate information concerning a woman's history of cardiotoxic cancer treatments, 14 it is useful as a summary measure of traditional risk factors that may increase the risk of CVD in both cancer and noncancer groups. To our knowledge, the current study is the first study among survivors of breast cancer to use the non-laboratory-based version of the Framingham risk score, which, unlike the full Framingham risk model, uses BMI rather than lipids in the estimation of CVD risk. Using the full risk model, a small, clinic-based study found that more women with breast cancer were considered to be "high risk" (10-year CVD risk >20%) compared with women without breast cancer in cross-sectional analyses. 15 Breast cancer cases in their study were selected from a cardio-oncology clinic, whereas comparison women were selected from an obstetrics and gynecology clinic. In contrast, in the results from the current study, taken from women with and without an incident breast cancer diagnosis selected from the same parent study cohort, we did not observe evidence of substantial differences in the non-laboratory-based Framingham risk score according to breast cancer status in either cross-sectional or longitudinal analyses. Cancer December 1, 2018 Numerous studies to date have found that weight gain and adverse body composition changes are common after a breast cancer diagnosis, 16 and some have speculated that unfavorable changes in these measures experienced by survivors of breast cancer may exceed those experienced in the course of normal aging, with potential implications for future CVD risk. This is believed to be particularly true for women treated with chemotherapy, although recent reviews have suggested that the magnitude of weight gain after chemotherapy among patients with breast cancer has decreased in more recent years. 16, 17 Some studies also have identified endocrine therapy as a predictor of weight gain in survivors of breast cancer, 18, 19 whereas others have not noted this association. [20] [21] [22] Although to the best of our knowledge the consequences of weight gain on CVD among women with breast cancer remain unclear, and could depend on the timing of weight gain relative to the diagnosis of breast cancer, excess adiposity measured at a single time point has been positively associated with CVD incidence and mortality after breast cancer. 12, 13 Thus weight, BMI, and other adiposity measures remain important outcomes to monitor in women with a breast cancer history.
Although we examined changes in weight from before to after diagnosis in women with an incident breast cancer diagnosis, prior studies have recruited women with a prevalent breast cancer diagnosis, and focused their analyses on weight changes occurring in the postdiagnosis period. In the Breast and Ovarian Surveillance Service (BOSS) Cohort Study, prospective cohort of individuals with a familial risk of breast and/or ovarian cancer, significantly greater gains in self-reported weight were observed in survivors of breast cancer (303 women) than age-matched women without breast cancer (307 women) from the same cohort. 23 However, to our knowledge, other studies, using either self-reported 24 or standardized measured weight, 25 have reported no significant differences in postdiagnosis weight gain between survivors of breast cancer and age-matched women without breast cancer. These findings, along with those of the current study, suggest that weight trajectories among women with breast cancer may not differ significantly from those among comparable women without a breast cancer history.
To our knowledge, the current study is the first to date to examine prediagnosis to postdiagnosis changes in blood pressure and CVD risk among women with an incident breast cancer. We also believe the current study is the largest study to date to compare changes in weight among women with breast cancer with those in a comparable group of women without breast cancer. A limitation of the current study is that we lacked information regarding lipid profiles and blood glucose, and therefore could not evaluate changes in these measures. We also lacked information concerning blood pressure and anthropometric measures from approximately the time of the diagnosis of breast cancer. Therefore, we were unable to determine whether any observed changes in weight and other factors in the breast cancer group occurred before or after diagnosis. However, the results of the current study suggest that, over a similar period, including the time surrounding both diagnosis and treatment among women with breast cancer, long-term changes in CVD risk factors do not differ substantially according to breast cancer status. The moderate participation rates among Sister Study participants invited for a second home visit also are a limitation, although participation rates were found to be similar between women with and without breast cancer, and the majority of enrollment characteristics that we evaluated did not differ significantly between women who did and did not choose to participate in the second visit (data not shown).
Among women with a breast cancer diagnosis, the risk of CVD is an important long-term health concern. In the current study, changes over time in 10-year CVD risk, adiposity measures, and blood pressure were found to be similar between women who developed an incident breast cancer and those who did not, suggesting that changes in common risk factors may not explain the increase in CVD mortality reported among survivors of breast cancer. 
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